Hepatitis C, Chronic Clinical Trial
Official title:
Randomized, Open-Label, Multicenter Study Examining the Effects of Duration of Treatment of PEGASYS® in Combination With Daily COPEGUS® + Amantadine in Patients With Chronic HCV After Relapse to Previous (Peg)IFN + Ribavirin Therapy.
The aim of this study is, to compare the relapse rate in chronic HCV patients with genotype 1 or 3 under the combination of standard dose Peg-Interferon alfa-2a (PEG-IFN alfa-2a), Ribavirin (RBV) and Amantadine (AMA) given for 72 weeks (group A), versus the same combination, given for 48 weeks (group B) in patients who relapsed to previous combination therapy to conventional or pegylated (PEG) Interferon alfa and Ribavirin. Relapse ist defined as percentage of patients with non-detectable HCV-RNA at end of therapy (week 48 GT1/ week 24 GT 3) who become HCV-RNA positive during a follow-up period of 24 weeks.
Status | Active, not recruiting |
Enrollment | 300 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Relapsers to previous combination therapy with (PEG-)IFN alfa-/Ribavirin and a negative HCV-RNA test result at the end of this regular treatment course and positive HCV-RNA test result during the follow-up period. - Termination of (PEG-)IFN alfa-/ribavirin therapy at least 3 months prior to enrolment - Chronic HCV infection genotype 1 or 3. - Serum HCV-RNA quantifiable at >100 IU/mL by COBAS AmpliPrep or another quantitative HCV-RNA PCR test (reported in IU) - Compensated liver disease (Child-Pugh A) - Exclusion of HCC in patients with cirrhosis or transition to cirrhosis. In patients with AFP >50 ng/mL an established assay for exclusion of HCC has to be done - Negative urine or blood pregnancy test - All fertile males and females must use two reliable forms of effective contraception (combined) during treatment with study drugs and 6 months post treatment Exclusion Criteria (at screening): - Hypersensitiveness to Interferon, PEG-IFN alfa-2a, Ribavirin and Amantadine or other ingredient of the drugs - Ongoing pregnancy or breast feeding - Male partners of women who are pregnant or with women without effective contraception - Signs or symptoms of hepatocellular carcinoma - Chronic HCV infection genotype 2, 4, 5 or 6 - Therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment < 6 months prior to the first dose of study drug and during study period. Exception: patients who have had a limited (< 7 days) course of acyclovir or valacyclovir for herpetic lesions < 1 month prior to the first administration of test drug are not excluded. - Any investigational drug < 6 weeks prior to the first dose of study drug - Positive test for anti-HAV IgM, HBsAg, anti-HBc IgM, anti-HIV - History or other evidence of a medical condition associated with chronic liver disease other than HCV - History or other evidence of decompensated liver disease or a Child-Pugh score > 6. - Hb <12 g/dL (<120 g/L) in women or <13 g/dL (<130 g/L) in men at screening - Any patient with an increased baseline risk for anemia or for whom anemia would be medically problematic - Neutrophil count <1,500 cells/mm3 and/or platelet count <90,000 cells/mm3 - Serum creatinin concentration >1.5 mg/dl - History of severe psychiatric disease, especially depression. - History of a severe seizure disorder that can not be stabilized by medication - History of immunologically mediated disease - Chronic pulmonary disease associated with functional limitation - History of severe cardiac disease - History of major organ transplantation except corneatransplantation - Evidence of severe illness, malignancy, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study - Thyroid dysfunction not adequately controlled - Evidence of severe retinopathy or clinically relevant ophthalmological disorder due to diabetes mellitus or hypertension - Evidence of active drug abuse within one year of study entry except of a prescribed stable opioid substitution - Take of Memantine during study period - Cardiomyopathy and myocarditis - AV-Block II° and III° - Pre-existing bradycardia < 55 counts/min - Known QT-interval (QTc after Bazett > 420 ms) or recognized U-waves or congenital QT-syndrome - History of severe ventricular arrhythmia incl. Torsade de pointes - Simultaneous therapy with Budipin or other medicine that extend the QT-interval like (e.g.antiarrhythmic drugs class IA and class III, antipsychotic drugs, tri- and tetracyclic antidepressants, antihistaminics, macrolide, gyrase inhibitors, Azol-antimykotics) - Patients with obstructive glaucoma - Patients with excitableness and confusion - Patients with delirium and exogenic psychosis in the anamnesis - Prostataadenome - Diuretic medication of the type combination Triamterene/ Hydrochlorothiazide - Inability or unwillingness to provide informed consent or abide by the requirements of the study |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | Universitätsklinikum des Saarlandes | Bad Homburg/ Saar | Saarland |
Germany | Charité, Campus Benjamin Franklin | Berlin | |
Germany | Charité, Campus Virchow-Klinikum, Med. Klinik (Gastroenterologie/ Hepatologie) | Berlin | |
Germany | Praxis Möller/ Heyne | Berlin | |
Germany | Klinikum der Ruhr-Universität Bochum | Bochum | Nordrhein-Westfalen |
Germany | Universitätsklinikum Bonn | Bonn | Nordrhein-Westfalen |
Germany | Klinikum Bremen-Mitte | Bremen | |
Germany | Universitätsklinikum Erlangen | Erlangen | Bayern |
Germany | J. W.-Goethe-Universität | Frankfurt | Hessen |
Germany | Universitätsklinikum Freiburg | Freiburg | Baden-Württemberg |
Germany | Klinikum der Medizinischen Fakultät der Martin-Luther Universität Halle-Wittenberg | Halle (Saale) | Sachsen-Anhalt |
Germany | Universitätsklinikum Hamburg-Eppendorf, Med. Klinik 1 | Hamburg | |
Germany | Medizinische Hochschule Hannover | Hannover | Niedersachsen |
Germany | Universitätsklinikum Heidelberg | Heidelberg | Baden-Württembeg |
Germany | Universitätsklinikum Schleswig-Holstein | Kiel | Schleswig-Holstein |
Germany | Klinikum der Universität Köln | Köln | Nordrhein-Westfalen |
Germany | Universitätsklinikum Schleswig-Holstein, Campus Lübeck | Lübeck | Schleswig-Holstein |
Germany | Johannes Gutenberg-Universität Mainz | Mainz | Rheinland-Pfalz |
Germany | Universitätsklinikum Mannheim | Mannheim | Baden-Würtemberg |
Germany | Klinikum rechts der Isar der TU München | München | Bayern |
Germany | Universitätsklinkum Münster | Münster | Nordrhein-Westfalen |
Germany | St-Josef-Hospital | Oberhausen | Nordrhein-Westfalen |
Germany | Klinikum der Universität Regensburg | Regensburg | Bayern |
Germany | Krankenhaus Barmherzige Brüder | Regensburg | Bayern |
Germany | Universität Rostock | Rostock | Mecklenburg-Vorpommern |
Germany | Universitätsklinikum Ulm | Ulm | Baden-Württemberg |
Germany | Klinikum der Universität Würzburg | Würzburg | Bayern |
Lead Sponsor | Collaborator |
---|---|
University of Hamburg | Hoffmann-La Roche, Universitätsklinikum Hamburg-Eppendorf |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | - Comparison of the rate of relapse under the combination of standard dose PegIFN alfa-2a, Ribavirin and Amantadine given for 72 vs. 48 weeks. | |||
Secondary | relationship between EVR during the first twelve weeks and SVR | |||
Secondary | virological response to the combination of standard dose defined as reduction of HCV RNA at week 4, 12, 24, 48 and 72 of treatment, separated between HCV-Genotypes. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03740906 -
Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting
|
||
Terminated |
NCT02465203 -
3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study
|
Phase 3 | |
Completed |
NCT02262728 -
An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease
|
Phase 2 | |
Completed |
NCT01429792 -
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
|
Phase 4 | |
Completed |
NCT02541409 -
Directly Observed Therapy for HCV in Chennai, India
|
Phase 2 | |
Completed |
NCT01846832 -
A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection
|
Phase 3 | |
Withdrawn |
NCT01608737 -
A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection
|
Phase 3 | |
Completed |
NCT01447446 -
An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C
|
N/A | |
Completed |
NCT01435226 -
GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection
|
Phase 2 | |
Completed |
NCT01435044 -
Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection
|
Phase 2 | |
Completed |
NCT02113631 -
Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir
|
N/A | |
Completed |
NCT01399619 -
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
|
Phase 3 | |
Terminated |
NCT01168856 -
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens
|
N/A | |
Completed |
NCT00725751 -
Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)
|
N/A | |
Completed |
NCT00793793 -
Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced
|
Phase 1 | |
Completed |
NCT00377182 -
A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.
|
Phase 2 | |
Completed |
NCT00375661 -
Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
|
Phase 4 | |
Completed |
NCT00723632 -
Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)
|
N/A | |
Completed |
NCT00704717 -
Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301)
|
N/A |